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Abstract
Background: Prostate cancer (PrCa) is the second most common cancer in Ireland. Many men present with locally
advanced or metastatic cancer for whom curative surgery is inappropriate. Advanced cancer patients are encouraged
to remain physically active and therefore there is a need to investigate how patients with metastatic disease tolerate
physical activity programmes. Physical activity reduces levels of systemic inflammatory mediators and so an aerobic
exercise intervention may represent an accessible and cost-effective means of ameliorating the pro-inflammatory
effects of obesity and subsequently decrease poor cancer-specific outcomes in this patient population. This study will
assess the feasibility and safety of introducing a structured aerobic exercise intervention to an advanced cancer
population. This study will also examine if the evasion of immune editing by circulating tumour cells (CTCs) is an
exercise-modifiable mechanism in obese men with prostate cancer.
Methods: This international multicentre prospective study will recruit men with metastatic prostate cancer. Participants
will be recruited from centres in Dublin (Ireland) and London (UK). Participants will be divided into exposed and
non-exposed groups based on body mass index (BMI) ≥ 25 kg/m2 and randomised to intervention and control groups.
The exercise group will undertake a regular supervised aerobic exercise programme, whereas the control group will
not. Exercise intensity will be prescribed based on a target heart rate monitored by a polar heart rate monitor. Blood
samples will be taken at recruitment and at 3 and 6 months to examine the primary endpoint of platelet cloaking
of CTCs. Participants will complete a detailed questionnaire to assess quality of life (QoL) and other parameters at
each visit.
Discussion: The overall aim of the ExPeCT trial is to examine the relationship between PrCa, exercise, obesity, and
systemic inflammation, and to improve the overall QoL in men with advanced disease. Results will inform future work
in this area examining biological markers of prognosis in advanced prostate cancer.
Trial registration: Clinicaltrials.gov NLM identifier: NCT02453139. Registered on 12 May 2015. This document contains
excerpts from the ExPeCT trial protocol Version 1.5, 28 July 2016.
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Background
Prostate cancer
Prostate cancer (PrCa) is the most common cancer
found in men in the developed world [1]. Many men
present with locally advanced or metastatic cancer for
whom curative surgery is inappropriate [2]. For these
men, increases in progression-free and overall survival
and quality of life (QoL) are the primary management
objectives, and new therapies and assisting lifestyle alter-
ations are increasingly needed.
Metabolic syndrome and prostate cancer
Obesity, known to be associated with a pro-
inflammatory, pro-thrombotic humoral milieu, confers a
worse prognosis in PrCa. Between 1990 and 2002, Irish
male obesity increased from 8% to 20%, with a further
47% of men overweight [3]. Metabolic syndrome (MS) is
a constellation of risk factors for cardiovascular disease,
with central adiposity and insulin resistance being the
most important components. Male hypogonadism, due
to androgen deprivation therapy (ADT)—the mainstay
of treatment for locally advanced and metastatic
PrCa—is an independent risk factor for the various com-
ponents of MS [4–8]. MS is present in 50% of all men
undergoing long-term ADT [9] and is associated with
progression of PrCa [10]. This may explain the excess
non-cancer mortality in this population [11].
MS is characterised by low-level chronic systemic in-
flammation. Increasing evidence suggests that substantial
cross-talk occurs between molecular pathways involved in
inflammation, coagulation, and obesity [12]. Elucidation of
how these pathways interact with PrCa cells may shed
light on why obesity disimproves PrCa prognosis.
Circulating tumour cells and prostate cancer
Circulating tumour cells (CTCs) are identified in the
blood in advanced cancer. Epithelial cells circulating in
the blood of patients with carcinoma can be identified
using various techniques including the ScreenCell® sys-
tem (ScreenCell, Paris, France). Increasing evidence sug-
gests that numbers of CTCs may have a prognostic role
in advanced PrCa. A prospective study of castration-
resistant PrCa found that ≥ 5 CTCs per 7.5 mL of blood
correlated with a poor prognosis [13]. When a variety of
clinical, serological, and pathological parameters were
considered, the model best predictive of survival was
based on baseline lactate dehydrogenase (LDH), baseline
CTC count, and fold-change in CTC count at monthly
intervals [14].
Natural killer cells and obesity
Natural killer (NK) cell numbers in blood and in solid
organs, as well as NK cell cytotoxicity and cytokine
secretion, are known to be reduced in obesity [15]. In
addition, obese people with hypertension, raised fasting
glucose, and an unfavourable lipid profile have less NK
cells than “metabolically healthy” obese patients. Obese
subjects have lower numbers of hepatic NK cells and
leptin receptor-positive cells compared with those of
normal weight [16]. The NK cell fraction of white blood
cells is sensitive to exercise [17], and five-fold increases in
NK concentrations following acute exercise have been
noted. Brief exercise upregulates molecular pathways in cir-
culating NK cells associated with cancer and cell communi-
cation [18]. In healthy young men, hypoxic exercise training
leads to enhanced in-vitro NK cell cytotoxicity [19].
Interactions between platelets and circulating tumour
cells
Despite the long-recognised association between cancer
and thromboembolism, it has been unclear whether the
thrombocytosis often seen in patients with metastases is
a consequence or cause of widespread dissemination of
the tumour. Accumulating evidence now shows that
platelets support tumour metastasis by various mecha-
nisms [20]. Platelets are involved in the arrest of CTCs
in the vasculature and, through endothelial interactions,
enable their extravasation. Platelets also secrete various
pro-oncogenic factors including platelet-derived growth
factor (PDGF) and vascular endothelial growth factor
(VEGF), and mediate pro-survival signals in ovarian can-
cer cells [21].
Tumour cell-induced platelet aggregation correlates
with metastatic potential, and may be due to “cloaking”
of tumour cells by adherent platelets. The interaction
between platelet cloaking of CTCs and tumour cell kill-
ing by NK cells is not completely understood. “Cloaking”
of CTCs by adherent platelets may impede NK cell
clearance of CTCs from the circulation, enhancing meta-
static spread. Thrombocytopaenic mice exhibited re-
duced tumour metastatic burden when the tumour cells
were NK cell sensitive, and in-vitro studies demonstrated
reduced NK tumourilytic activity when platelets aggre-
gated around tumour cells [22]. Platelets may enable
evasion of immune editing by NK cells by conferring a
“pseudonormal” phenotype on CTCs by encouraging
high-level surface expression of normal major histocom-
patibility complex (MHC) class 1 antigen by the tumour
cells [23].
In these pre-clinical studies there is an association be-
tween increased platelet-tumour cell interactions and
endpoints of metastasis and death in animal models, but
no clinical data exist as yet relating these interactions to
outcomes in human disease. The current proposed study
takes the current weight of evidence that platelet inter-
actions are important in metastasis, and attempts to
make the leap to demonstrate this in a clinical popula-
tion. Platelet “cloaking” may be enhanced in obese
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patients due to the pro-inflammatory, pro-thrombotic
state, and may be a mechanism for worse cancer-specific
outcomes in this group.
Prostate cancer and exercise
Several studies have shown that exercise may be protective
against aggressive PrCa although there is no evidence that
exercise protects against PrCa overall [24–27]. In PrCa pa-
tients there is solid evidence that exercise (especially group
exercise) improves muscular and aerobic endurance, re-
duces fatigue, and improves overall quality of life [28].
Physical activity reduces levels of systemic inflammatory
mediators [29], such as tumour necrosis factor (TNF)α,
and so exercise may represent an accessible and cost-
effective means of ameliorating the pro-inflammatory
effects of obesity. This effect of physical activity depends
on type, volume, and intensity, and does not depend
directly on weight loss [30].
Obesity and its biochemical effects may be influenced
by lifestyle changes such as exercise. As physical activity
reduces levels of systemic inflammatory mediators,
aerobic exercise may represent an accessible and cost-
effective means of ameliorating the pro-inflammatory
effects of obesity.
Methods and design
ExPeCT study objectives
The overarching hypothesis is that enhanced platelet
cloaking of CTCs in obese men with prostate cancer,
due to increased systemic inflammation, is a mechanism
underlying worse prognosis of cancer in these patients.
The aim is to test the following four hypotheses,
dividing the experimental and analytical work into four
separate projects:
1. Platelet cloaking of circulating PrCa tumour cells is
more prominent in men with obesity than without.
2. Regular exercise can ameliorate platelet cloaking.
3. The degree of platelet cloaking varies with levels of
systemic and primary tumour inflammation and
coagulability.
4. Expression of an obesity-associated lethality gene
signature leads to variation in platelet cloaking.
ExPeCT study design
This international multicentre prospective study will
recruit men with metastatic PrCa from five Irish hospi-
tals and one UK hospital. This study incorporates both an
observational component, with exposed and non-exposed
groups defined based on body mass index (BMI), and an
exercise component, with randomization to exercise and
control groups for a supervised exercise programme. Par-
ticipants with metastatic prostate cancer will be recruited
and divided into exposed (BMI ≥ 25 kg/m2) and non-
exposed groups (BMI < 25 kg/m2). All exposed and non-
exposed participants will be randomised to an exercise
group or a control group, helping to minimise bias. The
exercise group will participate in a 6-month exercise
programme, comprising a weekly group exercise class and
a home-based exercise programme. Participants will also
be encouraged to complete activity diaries. From baseline
(T0) to 3 months (T3), participants in the exercise arm will
meet in small groups with a chartered physiotherapist for
1 h per week. At these sessions, participants will be edu-
cated about using the Polar heart rate monitors, prescribed
their target exercise intensity, and complete a half-hour
group aerobic exercise class. From T3 to 6 months (T6)
continued aerobic exercise will be encouraged but classes
will not be supervised by a chartered physiotherapist. All
patients will be offered a personal exercise advice session
at the study end to discuss long-term compliance to phys-
ical activity guidelines. Any patients demonstrating a need
for further follow-up in relation to their physical activity
levels will be advised to attend their general practitioner
(GP) for a referral to the GP exercise scheme.
The study design consists of four main projects (Fig. 1):
Project 1: CTCs will be enumerated in the T0 samples.
Adherent platelets will be quantified and compared
between the exposed and non-exposed groups, and
correlated with clinicopathological parameters.
Project 2: The exercise group will undertake a regular
supervised aerobic exercise programme, whereas the
control group will not. T3 and T6 blood samples will be
assessed for CTC numbers and platelet cloaking. Changes
will be compared with the T0 sample, and between
exposed and non-exposed, and exercise and control
groups. Participants will complete a detailed questionnaire
to assess QoL and other parameters at each visit.
Project 3: Blood samples will be assessed for NK cell
number and activation, markers of systemic
inflammation, adipokines, and serum factors related to
platelet activation. The prostate needle core biopsies
(NCBs) will be examined microscopically for atrophy and
inflammation by morphology and immunohistochemistry,
with particular reference to NK cells. All variables will be
correlated with platelet cloaking.
Project 4: NCBs will be assessed for expression of an
obesity-associated lethality gene signature (whose genes
are known to play a role in obesity or platelet
aggregation and coagulation), and correlated with
platelet cloaking of CTCs.
ExPeCT participant selection criteria
Inclusion criteria
1. Written informed consent obtained before any
study-related procedures.
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2. Aged ≥ 18 years and male.
3. Histologically confirmed diagnosis of prostate
adenocarcinoma.
4. M1 metastatic disease as confirmed by computed
tomography (CT)/magnetic resonance imaging
(MRI) or by bone scan, excluding patients who only
have nodal metastatic disease.
5. Stable medical condition, including the absence of
acute exacerbations of chronic illnesses, serious
infections, or major surgery within 28 days prior to
randomisation.
6. Capable of participating safely in the proposed
exercise as assessed and signed off by a treating
physician involved in ExPeCT recruitment.
Exclusion criteria
1. Patients with a history of radical prostatectomy.
2. Patients with other known malignancy (except
non-melanoma skin cancers or fully excised
carcinoma in situ at any site).
Participant enrolment procedure
Potential patients will be enrolled to the study on the basis
of the inclusion/exclusion criteria. Enrolment of patients
will be undertaken by staff at the medical oncology clinics
at each recruiting site as well as members of the ExPeCT re-
search team who have been delegated this task by the
principle investigator (PI) (Fig. 2). Any queries about
eligibility will be addressed directly to the Chief Investigator.
Informed consent will be obtained by clinic staff or a
member of the ExPeCT research team according to the re-
quirements of International Conference on Harmonisation-
Good Clinical Practice (ICH-GCP).
Upon registration of new participants, a signature con-
firming eligibility for the trial must be obtained from a
treating physician involved in ExPeCT recruitment. Each
registered patient will receive a unique participant
identifier number (PIN). In order to ensure random
allocation of participants to each study group, the com-
puter programme Graphpad will be used to randomly
assign a treatment group to each PIN. When issuing
each PIN, two gatekeepers (1 in Ireland and 1 in the
UK) will inform the research team of the treatment allo-
cation of the participant. If a participant chooses to
withdraw from the study, all data obtained up to the
point of withdrawal will be carried forward unless re-
quested otherwise.
Study methodology
Demographic and clinical characteristics
A datasheet will be completed for each participant after
recruitment at T0 and at the T3 and T6 follow-up visits.
Data gathered will include date of birth, anthropometric
parameters (body weight, standing height, waist circum-
ference), blood pressure, routine laboratory data (serum
Fig. 1 Schematic of the four projects involved in the ExPeCT trial. BMI body mass index, CTC circulating tumour cell, H&E haematoxylin and eosin,
NK natural killer, TNF tumour necrosis factor
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prostate-specific antigen (PSA), haemoglobin, white cell
and platelet counts), site of metastasis, and cancer-related
data (stage and Gleason grade of cancer, details of current
and previous systemic and radiation therapy). Data will
also be recorded from three measures of physical function
including balance, lower limb strength, and gait speed.
These three measures will be completed with the patient
by the chartered physiotherapist. Participants may also be
asked to complete a structured interview session with the
chartered physiotherapist exploring attitudes towards exer-
cise. An overview of all data collected is included in Fig. 3.
Primary study endpoint
Platelet cloaking of circulating tumour cells
For each clinical review episode (at baseline and
after 3 and 6 months), 12–16 mL of blood drawn
from each patient into K2-EDTA tubes will be
filtered by a ScreenCell® Cyto kit within 4 h. CTC
enrichment depends on vacuum-assisted filtration
through a microporous membrane filter to separate
CTCs from other blood cells on the basis of size.
Three to five filters will be generated for each
participant, two of which will be stained with May-
Grunwald Giemsa, followed by a broad-spectrum
epithelial marker, and one to three reserved for
platelet cloaking assays and other relevant markers.
CTCs will be enumerated cytologically. The degree
of platelet adhesion to CTCs will be assessed by
immunohistochemistry. The number of CTCs with
adherent platelets will be counted, and the approxi-
mate number of platelets adherent to each cell will
be estimated.
Fig. 2 ExPeCT trial flowsheet
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Secondary study endpoints
Systemic and localized tumour inflammation and
coagulability
This part of the project consists of measurement of sys-
temic and prostate inflammation, markers of coagulation,
cytokines, and NK cells. The substrates for this work will
be blood samples taken from each participant at T0, T3,
and T6, and the original diagnostic NCB paraffin tissue
blocks. Examples of the serological and haematological
tests include adiponectin, leptin, and resistin.
Expression of lethality-associated genes
This project will evaluate expression of selected genes
known to be associated with PrCa progression, coagula-
tion, and stem cell-like phenotype in diagnostic NCBs.
Sections of formalin-fixed, paraffin-embedded tissue
blocks will be cut from each patient’s diagnostic prostate
NCB specimen. These sections will be dissected by
either laser capture microdissection or gross dissection.
Ribonucleic acid (RNA) will be extracted from the
microdissected tissue. Gene expression profiling will be
undertaken on diagnostic biopsy material using custom-
designed assays designed to detect only mRNA and to
traverse the exonic junction. Assays for the genes
CXCR4, PLA2G7, PTGER1, AVPR2, and HTR2B will be
employed. Quantitation of results of polymerase chain
reaction (PCR) will be undertaken using the ΔΔCt
method, comparing the Ct values of the samples of
interest with a control or calibrator such as a non-
treated sample or RNA from normal tissue. Diagnostic
material may be used for further gene expression ana-
lysis associated with obesity as part of the trial.
Quality of life assessment
All participants will complete a detailed questionnaire
after recruitment at T0, and again at T3 and T6. The
sections of the questionnaire are as follows:
1. Background details (age at diagnosis, domiciliary
situation, comorbidities, recent medications).
Fig. 3 ExPeCT SPIRIT figure. aNatural killer cell testing will only be performed at Irish sites. BMI body mass index, Circ. Circumference, FACT-P
Functional Assessment of Cancer Therapy scales for Men with Prostate Cancer, NCB needle core biopsy, PHQ Patient Health Questionnaire
Sheill et al. Trials  (2017) 18:456 Page 6 of 12
2. Smoking and alcohol.
3. Sleep (Pittsburgh Sleep Quality Index [31]).
4. Stress (Perceived Stress Scale – 4).
5. Depression (Patient Health Questionnaire
(PHQ)-9) [32].
6. Quality of life (FACT-P) [33].
7. Memory and cognition.
8. Physical activity.
9. Diet (dairy products, meat, vitamin D).
10. Pain (Brief Pain Inventory Scale) [34].
Some sections of the questionnaire are stand-alone vali-
dated instruments (such as the Functional Assessment of
Cancer Therapy scales for Men with Prostate Cancer
(FACT-P), which is designed to assess health-related
quality of life in this setting [33]). Others, such as the sec-
tions on physical activity and diet, are derived from a
prostate cancer-specific questionnaire used in the large
Physicians’ Health Study based at Harvard University [35].
Exercise programme
The exercise group will participate in a 6-month moderate-
to-vigorous intensity aerobic exercise programme compris-
ing a weekly class and a home-based aerobic exercise
programme. Participants will also be encouraged to
complete weekly activity diaries. From T0 to T3, partici-
pants in the exercise arm will meet in small groups with a
chartered physiotherapist for 1 h per week. During the first
class the participants will receive an introduction to the for-
mat of the exercise and will be educated on safe exercise
practices and strategies to monitor exercise exertion.
Each exercise participant will receive, and be educated
about using, a Polar heart rate monitor for the duration of
the study. Participants will exercise to a prescribed heart
rate range during class and home sessions. Exercise pre-
scription will progress in intensity and duration during
months 1 and 2 of the programme to reach the target 3 h
per week (180 min/week) of moderate-to-vigorous inten-
sity activity from month 3 onwards (Table 1). This level of
activity has been previously shown to be associated with a
33% reduction in all-cause mortality following prostate
cancer [36]. Participants will be encouraged to achieve this
target exercise in six 30-min sessions throughout the
week. However, flexibility will be allowed to facilitate lon-
ger or shorter session to a total of 180 min/week. Each ex-
ercise session must be of at least 10 min duration. The
research team has previously shown that similar aerobic
activity intensities can be achieved in cancer survivors
through a home-based walking programme and that a
Polar heart rate monitor was an acceptable means of mon-
itoring activity intensity [37].
During months 1–3, data from the Polar heart rate
monitor will be downloaded weekly to monitor adherence.
Participants will be scheduled to attend the research
centre once monthly from T3 to T6 to download data and
encourage ongoing adherence to the programme. In
addition, participants will receive weekly telephone con-
tact from the ExPeCT research team from T3 to T6 to
encourage adherence.
The control group will not be given specific advice re-
garding exercise beyond that considered usual medical
care, and will not be invited to participate in the aerobic
exercise group. Participants will be reviewed at T3 and
T6 following the baseline visit and anthropometric
measurements and further blood samples taken. Partici-
pants assigned to the control group will be offered a per-
sonal exercise advice session following completion of the
T6 assessment.
Table 1 Exercise intensity during supervised classes
Supervised exercise classes Exercise intensity (% heart rate reserve) by baseline fitness group Duration
Poor Fair Average (min)
Month 1 Week 1 40–50% 50–60% 55–65% 20
Week 2 40–50% 50–60% 55–65% 20
Week 3 45–55% 55–65% 60–70% 20
Week 4 45–55% 55–65% 60–70% 30
Month 2 Week 5 50–60% 60–70% 65–75% 30
Week 6 50–60% 60–70% 65–75% 30
Week 7 55–65% 65–75% 65–75% 30
Week 8 55–65% 65–75% 65–75% 30
Month 3 Week 9 60–70% 65–75% 65–75% 30
Week 10 60–70% 65–75% 65–75% 30
Week 11 60–75% 65–75% 65–75% 30
Week 12 60–75% 65–75% 65–75% 30
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Exercise prescription
Participants will be asked to self-rate their baseline
activity levels as one of three categories as per American
College of Sports Medicine (ACSM) guidelines:
1) Sedentary or minimally active, not completing any
moderate to vigorous activity (equivalent to poor
fitness levels).
2) Sporadic physical activity, suboptimal exercise
(equivalent to fair fitness levels).
3) Habitual physical activity, regular moderate to
vigorous exercise (equivalent to average fitness levels).
Exercise intensity will be prescribed using individualised
heart rate reserve (HRR) ranges in accordance with the
ACSM guidelines. The following formula will be used to
calculate HRR and heart rate (HR) range prescriptions:
(target % × [maximum HR – resting HR] + resting HR). For
each participant, age-predicted maximal HR will be calcu-
lated using the following equation: (206.9 – [0.67 × age])
[38]. Participants with self-rated ‘poor’ fitness levels
(category 1) will commence the programme at an aerobic
intensity of 40–50% HRR. Those with self-rated ‘fair’ fit-
ness levels (category 2) will commence the programme at
an aerobic intensity of 50–60% HRR, and those with self-
rated ‘average’ fitness levels (category 3) will commence
the programme at 55–65% HRR. The duration and fre-
quency of the home exercise programme sessions is out-
lined in Table 2.
Patients will also be encouraged to use the Borg
Breathlessness Scale. Using this scale, participants will
give a subjective rating of perceived exertion. It is a
widely used and reliable indicator to monitor and guide
exercise intensity [39]. The scale allows individuals to
subjectively rate their level of exertion during exercise
and can be used to correlate exertion levels with exercise
heart rates [40]. The Borg scale will be particularly valu-
able with participants on beta blockers as measures of
exercise intensity are inaccurate or dampened on these
medications and polar monitors may not reflect an ac-
curate heart rate during exercise.
Forms of aerobic exercise undertaken at the supervised
exercise classes will specifically avoid activities which
may be associated with higher risk (e.g. the use of
rowing machines in participants with lumbar spinal
metastases). Walking on treadmills is a low-risk exer-
cise activity.
Exercise follow-up
Participants will be invited to attend outpatient
departments 6 months after T0 and the trial datasheet,
questionnaire, and physical function measures will again
be completed. Blood samples will be obtained in the
same fashion as for the T0 visit. All patients will be
offered a personal exercise advice session at study end to
discuss long-term compliance to physical activity guide-
lines. Any patients demonstrating a need for further
follow-up in relation to their physical activity levels will
be advised to attend their GP for a referral to the GP
exercise scheme. After this visit, participants will be
thanked for their involvement and discharged from
the study.
Table 2 Home-based exercise intensity
Home-based walking programme Exercise intensity (% heart rate reserve) by baseline fitness group Time
Poor Fair Average Days/week Duration (min)
Month 1 Week 1 40–50% 50–60% 55–65% 2 20
Week 2 40–50% 50–60% 55–65% 3 20
Week 3 45–55% 55–65% 60–70% 3 20
Week 4 45–55% 55–65% 60–70% 3 30
Month 2 Week 5 50–60% 60–70% 65–75% 3 30
Week 6 50–60% 60–70% 65–75% 4 30
Week 7 55–65% 65–75% 65–75% 4 30
Week 8 55–65% 65–75% 65–75% 5 30
Month 3 Week 9 60–70% 65–75% 65–75% 5 30
Week 10 60–70% 65–75% 65–75% 5 30
Week 11 60–75% 65–75% 65–75% 5 30
Week 12 60–75% 65–75% 65–75% 5 30
Month 4 Weeks 13–16 60–75% 65–75% 65–75% 6 30
Month 5 Weeks 17–20 60–75% 65–75% 65–75% 6 30
Month 6 Weeks 12–24 60–75% 65–75% 65–75% 6 30
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Study duration
The study is scheduled to last for 4 years; initial funding
was drawn down in April 2014. Enrolment commenced
in November 2014 and closed in May 2017 in order to
allow enrolled participants to complete their 6 months
of follow-up and exercise programme and for all labora-
tory work and analysis to be finished before the study
completion date.
Patient withdrawal and off-study procedure
Patients are free to withdraw from participation in the
study at any time upon request. An off-study form must
be completed and sent to the ExPeCT research team if a
patient withdraws from the study or leaves due to an-
other reason (e.g. study completion, extraordinary med-
ical circumstances, lost to follow-up).
Incident reporting
The occurrence and severity of any incidents from the
time of consent to completion of the programme at
6 months will be recorded by the chartered physiother-
apist on a standardised reporting form (e.g. adverse
events occurring as a result of exercise or adverse
reactions to study blood draws). All incidents will be re-
ported to the site PI. Incidents will be followed until
resolution or until a patient withdraws from the study or
leaves due to another reason (e.g. study completion,
extraordinary medical circumstances, lost to follow-up).
Recurrent incidents in the same patient will be counted
as separate incidents.
Data management
The ExPeCT research team will be the only people with
access to the data collected in the course of this project.
Data analysis will be performed at St. James’s Hospital
by the in-house bioinformatics team and other members
of the ExPeCT research team. At the end of the
study period, when all analysis is complete, data will
be retained by the ExPeCT research team. Data will
be securely stored for up to 10 years with the option
of requesting ethical permission for a prolonged stor-
age time.
Sample size
We will recruit 200 participants over the lifetime of the
study, evenly divided between the exercise group and
the control group. To calculate the power of the study,
we used data from a previous study of ovarian cancer
cell lines which showed approximately 2% platelet adhe-
sion [21]. A standard deviation (SD) varying from 2% to
10% would enable us to detect a difference of platelet
cloaking of between 0.79% and 3.9%. Research into this
area is at an early stage and the clinical importance of
specific incremental changes in the degree of platelet
cloaking is as yet uncertain, but its elucidation is beyond
the scope of this study.
With regard to the detection of changes in platelet
cloaking with time, and taking the same assumptions
regarding SD of platelet adhesion in PrCa CTCs as in
project 1, we will be able to detect a change of 1.8%
platelet cloaking between any two time points in the 100
participants in each of the exercise and the control
groups, determined by paired t testing. A SD varying
from 2% to 10% would enable us to detect a difference
of platelet cloaking of between 0.56% and 2.8%. General-
ised linear mixed models will be employed in order to
account for the correlation between multiple measure-
ments in the same experimental subject.
Statistical analysis
Project 1 will compare the number of cloaked platelets,
comparing healthy weight and overweight men using
either the t test or the non-parametric Mann-Whitney
test, depending on the normality of the data. Linear re-
gression models will be used to test the association be-
tween obesity and extent of platelet cloaking, adjusting for
potential confounders such as age, use of medications,
and smoking. If the data are not normally distributed then
a log transformation will be employed. In addition to com-
paring overweight and healthy weight men as a binary ex-
posure, BMI will be modelled as an ordinal variable
(<18.5, 18.5–24.9, 25.0–27.4, 27.5–29.9, 30+) and as a con-
tinuous variable and to test for linear trends with the log
likelihood ratio test of nested models.
Project 2 will compare measurements of platelet cloak-
ing at baseline and months 3 and 6 follow-up time
points among men randomised to the exercise and con-
trol arms, in both the exposed (BMI ≥ 25) and non-
exposed (BMI < 25) groups. Intention-to-treat analyses
will use linear mixed-effect models to incorporate each
biomarker for a given participant over time. BMI will
also be stratified to look at potential effect modification.
To estimate longitudinal changes in quality of life scores
from baseline, the primary analysis will be carried out
using a mixed-effects model for repeated measures.
Project 3 will examine the extent of the inflammatory
infiltrate in diagnostic NCBs. All variables will be corre-
lated with CTC numbers and platelet cloaking using
basic descriptive statistics such as Pearson correlation
coefficients for continuous variables and simple t tests
for categorical variables. In the event of skewed distribu-
tions or sparse data, we will use non-parametric tests
such as the Spearman correlation and Mann-Whitney.
Moreover, a principal component analysis will be under-
taken to estimate the proportion of variability in platelet
cloaking and CTC number which is explained as a func-
tion of the obesity inflammatory biomarkers. The bio-
markers will be modelled as principal components in the
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linear regression and adjusted for potential confounders
such as age, smoking, and other factors.
Project 4: Generalized linear regression models will be
used to examine whether obesity is associated with ex-
pression of each of the five markers in the tumour tis-
sue, adjusting for potential confounders such as age and
smoking status, as well as clinical features. Obesity will
be dichotomised as BMI greater or less than 25, and we
will also model BMI as a continuous variable and exam-
ine tests for trend. The expression of each marker will be
assessed with respect to the extent of platelet cloaking
(high, intermediate, and low). The categorisation of platelet
cloaking as high, intermediate, and low is dependent on the
proportion of CTCs with adherent platelets (high > 75%,
intermediate 25–75%, low < 25%). A gene score will be
created by ranking individuals across expression of each
gene in tertiles, assigning points for each marker as lowest
tertile = 0, middle tertile = 1, upper tertile = 2, and calculat-
ing a summary score.
Ethics and research governance
The study protocol and other documentation have been
approved by NRES Committee London—Camden &
Islington (REC reference 14/LO/1859), The Mater
Misericordia Hospital Research Ethics Committee, Dublin
(REC reference: 1/378/1760), Beaumont Hospital Ethics
(Medical Research) Committee, Dublin (REC Reference
15/73), SJH/AMNCH Research Ethics Committee, Dublin
(REC Reference: 2014-11 List 41 (6)) and St Luke’s
Radiation Oncology Network, Dublin (REC Number not
assigned. Trial referred to as ICORG 15-21 (sponsorship
identifier)).
Cancer Trials Ireland is the sponsor for the Irish sites on
this study (Protocol Number CTRIAL-IE (ICORG) 15-21).
Discussion
Many patients diagnosed with PrCa are not suitable for
radical therapy because of the extent or grade of disease.
In those patients who have potentially curable disease,
obesity and its complications may make radical surgery
impractical. ADT is itself a cause of obesity and meta-
bolic syndrome. For all of these reasons, men with PrCa
who are obese are less likely to be treated with curative
intent. Medical therapy is improving for the cardio-
vascular complications of obesity which are the major
competing cause of death in these men. As control of
obesity-related cardiovascular risk factors improves,
aggressiveness of PrCa becomes more important in de-
termining the cause of mortality. It is known that obese
men have a worse outlook regarding cancer-related mor-
tality than non-obese men. The combination of an age-
ing population with an increased PrCa incidence,
increasing obesity prevalence, and improved manage-
ment of cardiovascular risk factors means that in the
future, simply put, more men are going to die as a result
of the deleterious effect of being overweight in advanced
PrCa. Demonstration that platelet cloaking is a mechan-
ism by which obesity disimproves PrCa survival would
suggest that therapies targeted at points along the
pathway of platelet activation could be efficacious. For
example, adiponectin supplementation or blockade of
interleukin (IL)-6 or TNFα could be useful. Comparison
of the expression of lethality-associated genes between
the primary site and CTCs could highlight genes which
are upregulated as part of the metastatic pathway, with
potential for targeted therapy.
ExPeCT aims to elucidate a potential mechanism by
which obesity confers a worse prognosis in PrCa, two
increasingly prevalent diseases in the Western world.
ExPeCT hopes to show that a low-cost, accessible
exercise programme can improve QoL and potentially
ameliorate the effects of obesity through alterations in
the systemic adipokine and inflammatory mediator
profile.
Trial status
ExPeCT trial protocol Version 1.5, 28 July 2016.
Recruitment was initiated in October 2014 and con-
tinued until May 2017. Data collection is ongoing for
enrolled participants and is expected to conclude in
November 2017.
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